REVERSOL Drug Patent Profile
✉ Email this page to a colleague
When do Reversol patents expire, and what generic alternatives are available?
Reversol is a drug marketed by Organon Usa Inc and is included in one NDA.
The generic ingredient in REVERSOL is edrophonium chloride. There are three drug master file entries for this compound. Additional details are available on the edrophonium chloride profile page.
Summary for REVERSOL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 89 |
Formulation / Manufacturing: | see details |
DailyMed Link: | REVERSOL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for REVERSOL
US Patents and Regulatory Information for REVERSOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon Usa Inc | REVERSOL | edrophonium chloride | INJECTABLE;INJECTION | 089624-001 | May 13, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |